Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of BME will - over the next 2 Weeks and hit - by . In that time frame, BME's share price is expected to range between - and -.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No Data | |||||||||||||||||||
BME shares fell -1.27% in Friday, March 13, 2026's trading session, dropping from a previous close of $40.23 to move at $39.72. The stock demonstrated notable intraday movement (see BME's key stats for a full breakdown), fluctuating between $39.58 and $40.43, a +2.13% trading range. While recent weeks have seen some volatility, BME has managed to secure a -6.10% drop over the past 2 weeks. The downward price movement was accompanied by increased trading volume, with approximately 30.04K shares changing hands, 3.13K more than the previous session. This amounted to $1.19M in total market activity.
Will BME Continue Its Trend?
According to analyst ratings and projections for BME, BlackRock Health Sciences Trust shares are anticipated to remain stable by -, potentially reaching - per share by January 1, 1970. Short-term technical indicators for BME currently suggest a bearish sentiment. This aligns with the stock's recent performance, as it has recorded 19 negative trading days within the past 30 sessions. Based on the BME stock forecast, now is not the best time to buy BME stock because its current trading price is - our predicted value, hinting at a possible . For deeper insights, view our sentiment analysis on BME covering social and institutional perspectives.
BME Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into BME's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 14.45% to 30.72%) suggest the stock is experiencing strong bearish momentum. The 50-day RSI, at 45.59%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 49.91%, maintains a neutral outlook for the long term. Insights into BME's shareholder base show how institutional investors are positioning themselves during these momentum shifts

